Change over period: —
NSE · CONCORDBIO
CONCORDBIO
-64.7% from the 52-week high · +1.1% above the low
Concord Biotech Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2023-08-18. Concord Biotech Limited is an India-based research and development driven biopharma company. The firm is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The firm manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic processes and finished formulations. The company manufactures fermentation and semi-synthetic based products in the therapeutic segments, such as immunosuppressants, anti-bacterial, oncology, anti-fungal and others. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Vancomycin Hydrochloride, Micafungin Sodium, Mupirocin, Romidepsin, Dactinomycin, and Pravastatin Sodium, among others. The company also has a pipeline of API products under development. Its API products under development include Polymyxin B, Fidaxomicin, Doxorubicin, and others. The firm provides products in the critical care, immunology, nephrology, and transplant medicine segments.
The short version. CONCORDBIO reported revenue of ₹309 crore for Sep 2026, up 25.1% from a year earlier. Net profit was ₹71 crore (up 10.9% year on year). Return on equity was 12.9% in Mar 2026. Promoter holding was 44.09% in Sep 2026, up 0.01 points over 8 quarters.
1 · The price
How has the stock traded?
CONCORDBIO trades 64.7% below its 52-week high and 1.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹309 cr.
Sep 2026 net profit of ₹71 cr.
2.8 pts lower than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 309 | 257 | 326 | 278 | 247 | 204 | 430 | 244 |
| Net profit | 71 | 59 | 89 | 64 | 64 | 44 | 140 | 76 |
| Net margin % | 22.9 | 22.7 | 27.2 | 23.2 | 25.7 | 21.6 | 32.7 | 31.1 |
| EPS (₹) | 3.38 | 2.8 | 4.24 | 3.08 | 3.04 | 2.11 | 6.71 | 3.63 |
Annual
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 1055 | 1200 | 1017 |
| Net profit | 261 | 372 | 308 |
| Net margin % | 24.7 | 31.0 | 30.3 |
| EPS (₹) | 12.47 | 17.76 | 14.73 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 12.9% in Mar 2026; debt to equity is 0.00.
Profitability · 3 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Return on equity % | 12.9 | 20.5 | 20.2 |
| Return on capital % | 16.6 | 26.8 | 26.4 |
| EBITDA margin % | 37.6 | 44.3 | 44.3 |
| Net margin % | 23.6 | 29.9 | 29.3 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Up 0.01 pts over 8 quarters.
Down 1.05 pts over 8 quarters.
Up 1.29 pts over 8 quarters.
+14 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 | 44.08 | 44.09 | +0.01 |
| FII | 8.33 | 9.35 | 9.11 | 8.03 | 7.58 | 7.8 | 7.52 | 7.28 | -1.05 |
| DII | 9.66 | 9.16 | 8.87 | 9.55 | 9.58 | 9.22 | 9.36 | 10.95 | +1.29 |
| Public | 37.93 | 37.41 | 37.95 | 38.33 | 38.76 | 38.9 | 39.03 | 37.68 | -0.25 |
Mutual fund holdings · Oct 2026
61 schemes hold this stock
47 the month before.
- DSP Healthcare Fund2.46% of NAV
- SBI Healthcare Opportunities Fund1.97% of NAV
- Baroda BNP Paribas Health and Wellness Fund1.83% of NAV
- DSP Small Cap Fund1.61% of NAV
- Baroda BNP Paribas Innovation Fund1.18% of NAV
- EDELWEISS SMALL CAP FUND1.05% of NAV
- ITI Flexi Cap Fund0.87% of NAV
- SBI Balanced Hybrid Fund0.75% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for CONCORDBIO are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about CONCORDBIO
What is the CONCORDBIO share price?
CONCORDBIO (CONCORDBIO) last closed at ₹556.40, down 0.82% on the day. Its 52-week range is ₹554.80 to ₹1,587.50.
What is the market cap of CONCORDBIO?
CONCORDBIO has a market capitalisation of about ₹11,739 crore. Its price-to-earnings ratio is 41.7.
How are CONCORDBIO's latest results?
CONCORDBIO reported revenue of ₹309 crore for Sep 2026, up 25.1% from a year earlier. Net profit was ₹71 crore (up 10.9% year on year). Return on equity was 12.9% in Mar 2026. Promoter holding was 44.09% in Sep 2026, up 0.01 points over 8 quarters.
Who owns CONCORDBIO?
As of Sep 2026, shareholding was: Promoter 44.09%, FII 7.28%, DII 10.95%, Public 37.68%.
How many mutual funds hold CONCORDBIO?
61 mutual fund schemes held CONCORDBIO in October 2026. That compares with 47 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 03 Sep 2025 · Final Dividend - Rs. 10.7
- 21 Jun 2024 · Dividend - Rs. 8.75
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.